Cerep has announces the extension of its pharmaco-informatics alliance with Pfizer for up to three years (through 2009).
Through this alliance, beginning in 2002, Pfizer has accessed Cerep’s BioPrint® data and the derived pharmaco-informatics methodologies. As part of the alliance, Pfizer and Cerep collaborate on the enhancement of BioPrint® and the derived pharmaco-informatic methods with Pfizer compounds. The goal of the collaboration is to provide early tools for in vitro safety evaluation of lead compounds.
"We are particularly happy to announce the extension of this alliance with Pfizer. We feel that the first four years of the collaboration have established and validated the use of the BioPrint® concept as a key technology to support decision-making.
We appreciate the effort that Pfizer has put into the alliance and we feel that the two companies, working together, can continue to make significant advances in the development and validation of predictive technologies", commented Thierry Jean, President & CEO, Cerep.